BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 2,972 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $82.39, for a total transaction of $244,863.08. Following the transaction, the executive vice president now directly owns 55,332 shares in the company, valued at approximately $4,558,803.48. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of BioMarin Pharmaceutical Inc. (BMRN) opened at $86.16 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.70 and a debt-to-equity ratio of 0.29. The company has a market cap of $15,130.00, a price-to-earnings ratio of -94.68 and a beta of 1.73. BioMarin Pharmaceutical Inc. has a 1 year low of $77.04 and a 1 year high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.06). The business had revenue of $358.31 million during the quarter, compared to the consensus estimate of $346.24 million. BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. research analysts forecast that BioMarin Pharmaceutical Inc. will post -0.67 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. First Manhattan Co. lifted its position in shares of BioMarin Pharmaceutical by 104.2% in the fourth quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 625 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth $112,000. Commerce Bank bought a new stake in shares of BioMarin Pharmaceutical in the third quarter worth $209,000. IFG Advisory LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth $212,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of BioMarin Pharmaceutical in the third quarter worth $220,000.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.